Elicio Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
ELTX$1.61-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (unaudited)
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
For the Three Months Ended March 31, 2026
| Common Stock · Treasury Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders'Equity (Deficit) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||
| Balance as of December 31, 2025 | 17,814,762 | $178 | (14,455) | $(150) | $235,407 | $(127) | $(233,672) | $1,636 |
| Issuance of common stock from at-the-market offering, net of issuance costs of $0.2 million | 819,157 | 8 | — | — | 7,769 | — | — | 7,777 |
| Issuance of common stock upon exercise of options | 20,431 | — | — | — | 100 | — | — | 100 |
| Stock-based compensation | — | — | — | — | 868 | — | — | 868 |
| Foreign currency translation adjustment | — | — | — | — | — | 5 | — | 5 |
| Net loss | — | — | — | — | — | — | (11,823) | (11,823) |
| Balance as of March 31, 2026 | 18,654,350 | $186 | (14,455) | $(150) | $244,144 | $(122) | $(245,495) | $(1,437) |
For the Three Months Ended March 31, 2025
| Common Stock · Treasury Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders'(Deficit) Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||
| Balance as of December 31, 2024 | 11,043,837 | $110 | (14,455) | $(150) | $183,004 | $(175) | $(194,101) | $(11,312) |
| Issuance of common stock from at-the-market offering, net of issuance costs of $0 million | 106,823 | 1 | — | — | 834 | — | — | 835 |
| Issuance of common stock upon exercise of options | 1,628 | — | — | — | 7 | — | — | 7 |
| Conversion of senior note payable into common stock, net of issuance costs of $0.3 million | 3,500,573 | 35 | — | — | 20,141 | — | — | 20,176 |
| Issuance of common stock and warrants from the January 2025 Offering, net of issuance costs of $0.8 million | 1,261,830 | 13 | — | — | 9,130 | — | — | 9,143 |
| Issuance of common stock upon the exercise of common warrants | 68,500 | 1 | — | — | 715 | — | — | 716 |
| Stock-based compensation | — | — | — | — | 517 | — | — | 517 |
| Foreign currency translation adjustment | — | — | — | — | — | 31 | — | 31 |
| Net loss | — | — | — | — | — | — | (11,209) | (11,209) |
| Balance as of March 31, 2025 | 15,983,191 | $160 | (14,455) | $(150) | $214,348 | $(144) | $(205,310) | $8,904 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.